Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 20, 2020 08:00 ET | Source: Immunomedics

Immunomedics to Report Results for the Fourth Quarter and Full Year 2019 and Host Conference Call and Webcast on February 27, 2020

MORRIS PLAINS, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
February 14, 2020 08:00 ET | Source: Immunomedics

Immunomedics Appoints Dr. Loretta Itri Chief Medical Officer

MORRIS PLAINS, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
February 06, 2020 08:00 ET | Source: Immunomedics

Immunomedics to Participate in Guggenheim Healthcare Talks | Oncology Day

MORRIS PLAINS, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
December 26, 2019 08:00 ET | Source: Immunomedics

Immunomedics Announces FDA Acceptance for Filing of Biologics License Application Resubmission for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer

Prescription Drug User Fee Act (PDUFA) target action date set for June 2, 2020 MORRIS PLAINS, N.J., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the...
December 09, 2019 16:01 ET | Source: Immunomedics

Immunomedics Announces Closing of Public Offering of Common Stock

MORRIS PLAINS, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
December 04, 2019 20:29 ET | Source: Immunomedics

Immunomedics Announces Pricing of Public Offering of Common Stock

MORRIS PLAINS, N.J., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
December 03, 2019 16:01 ET | Source: Immunomedics

Immunomedics Announces Proposed Public Offering of Common Stock

MORRIS PLAINS, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
December 03, 2019 08:00 ET | Source: Immunomedics

Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan

MORRIS PLAINS, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
November 13, 2019 08:00 ET | Source: Immunomedics

Immunomedics to Present at Upcoming Healthcare Conferences

MORRIS PLAINS, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
October 30, 2019 16:00 ET | Source: Immunomedics

Immunomedics Reports Third Quarter 2019 Results and Provides Corporate Update

TROPHY-U-01 Reached Target Enrollment in Cisplatin-Eligible Cohort of 100 Patients First NSCLC Patient Dosed in Trop-2-Enriched TROPiCS-03 Study BLA Resubmission Targeted for Late...